Potent inhibitors of SARS-CoV-2 3C-like protease derived from N-substituted isatin compounds

Eur J Med Chem. 2020 Nov 15:206:112702. doi: 10.1016/j.ejmech.2020.112702. Epub 2020 Aug 1.

Abstract

SARS-CoV-2 3C-like protease is the main protease of SARS-CoV-2 and has been considered as one of the key targets for drug discovery against COVID-19. We identified several N-substituted isatin compounds as potent SARS-CoV-2 3C-like protease inhibitors. The three most potent compounds inhibit SARS-CoV-2 3C-like protease with IC50's of 45 nM, 47 nM and 53 nM, respectively. Our study indicates that N-substituted isatin compounds have the potential to be developed as broad-spectrum anti-coronavirus drugs.

Keywords: COVID-19; In vitro assay; N-substituted isatin compounds; SARS-CoV-2 3C-like protease; Structure-activity relationship.

MeSH terms

  • Antiviral Agents / pharmacology
  • Antiviral Agents / therapeutic use*
  • Betacoronavirus / drug effects*
  • Coronavirus 3C Proteases
  • Cysteine Endopeptidases
  • Humans
  • Isatin / analogs & derivatives
  • Isatin / chemical synthesis
  • Isatin / therapeutic use*
  • Models, Molecular
  • Molecular Docking Simulation
  • Protease Inhibitors / chemical synthesis
  • Protease Inhibitors / pharmacology
  • Protease Inhibitors / therapeutic use*
  • SARS-CoV-2
  • Structure-Activity Relationship
  • Viral Nonstructural Proteins / antagonists & inhibitors*

Substances

  • Antiviral Agents
  • Protease Inhibitors
  • Viral Nonstructural Proteins
  • Isatin
  • Cysteine Endopeptidases
  • Coronavirus 3C Proteases